Lilly’s Psoriasis Drug Taltz Set For Second Quarter Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
Ixekizumab had a smooth FDA approval, with no advisory committee needed for the second member of the IL-17 inhibitor class.
You may also be interested in...
Lilly Management Reorg Brings In Shaw To Oversee Bio-Medicines
Shaw is the former US President of rival Novartis and a rising figure in big pharma. She will take over the role previously held by Ricks, who became CEO Jan. 1. Conterno will assume President USA role.
Valeant’s Brodalumab Delayed By FDA As REMS Is Negotiated
FDA notified the company the US review goal date for the psoriasis pill has been extended three months from Nov. 16 to Feb. 16.
Novartis Pulling Out All The Stops To Amp Up Entresto Sales
The company has set a sales goal of $200m for Entresto in 2016, not an enormous amount for a drug that is expected to eventually be a multi-billion dollar seller, but ambitious given its slow first quarter start.